Publications by authors named "F B Hagemeister"
Background: Rituximab and lenalidomide is a preferred option for relapsed indolent B cell non-Hodgkin lymphoma. Obinutuzumab may be a superior combination partner with lenalidomide given enhanced antibody dependent cellular cytotoxicity and phagocytosis compared to rituximab. Our aim was to determine the recommended phase 2 dose, safety, and activity of lenalidomide in combination with fixed dose of obinutuzumab in relapsed and refractory indolent B cell non-Hodgkin lymphoma.
View Article and Find Full Text PDFArticle Synopsis
- Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are types of slow-growing non-Hodgkin lymphomas that typically have a median survival of about 20 years, but current treatments are not curative, prompting a need for new therapies.
- A phase 2 clinical trial tested an innovative combination treatment of lenalidomide, rituximab, and ibrutinib (IRR) on previously untreated patients with FL and MZL, focusing on progression-free survival (PFS) over 24 months.
- Results showed that after an average follow-up of about 65 months, the estimated PFS was 78.8% at 24 months and 59.7
Article Synopsis
- * Analyzing data from 269 DLBCL patients, the researchers found that higher TIL-B abundance correlates with better patient survival and distinct gene expression profiles, indicating a strong association with positive immune responses.
- * The findings suggest that TIL-B frequency serves as a robust prognostic biomarker, exceeding previous classifications, and highlights the importance of TIL-Bs in guiding DLBCL treatment strategies.
Article Synopsis
- * Research using single-cell RNA sequencing revealed that patients experiencing prolonged cytopenia had an increase in specific cytotoxic T cells that produce high levels of interferon (IFN)-γ, which is linked to this condition.
- * The findings suggest that IFN-γ negatively impacts the function of hematopoietic stem cells (which produce blood cells), and potential treatments could involve targeting IFN-γ with either thrombopoietin agonists or neutralizing antibodies.
Article Synopsis
- Primary mediastinal large B-cell lymphoma (PMBCL) is a rare and aggressive form of non-Hodgkin lymphoma, with most patients responding well to immunochemotherapy, though relapses indicate a tough prognosis.
- This study examined the clinical features and immune cell makeup in 12 PMBCL patients to identify potential prognostic markers, particularly focusing on macrophage presence through specialized tissue analysis.
- Findings suggest that higher levels of certain macrophages (like PD-L1 macrophages) in biopsies correlate with better outcomes, hinting at the need for further research to create reliable biomarkers that could guide treatment decisions for PMBCL.